Tirzepatide 10–100 mg

Tirzepatide for research: identity and specifications

Tirzepatide (CAS 2023788-19-2) is a synthetic 39-residue peptide that acts as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, studied in laboratory research on receptor pharmacology and metabolic signaling. Supplied in vials of 10 to 100 mg, lyophilized powder, with no fillers, carriers or excipients, at ≥98% purity by HPLC, with the lot-specific value reported on the certificate of analysis.

Scientific background

Its sequence is based on native GIP and incorporates Aib residues and a C20 fatty diacid side chain at Lys20, which supports albumin binding. In assays using cells that express the GIP and GLP-1 receptors, the compound is investigated for binding affinity, relative potency at each receptor and cyclic AMP (cAMP) generation, including studies of selectivity and signaling bias between the two targets.

Preclinical literature uses tirzepatide in insulin and glucagon secretion assays in islets and pancreatic cell lines and in rodent models of glucose metabolism, always under controlled bench conditions and without extrapolating results to human or veterinary use.

• Dual agonism of the GIP and GLP-1 receptors in cell-based assays
• Relative potency and cAMP signaling bias at each receptor
• Insulinotropic and glucagonostatic responses in experimental models
• Structure-activity relationship of acylated incretin analogs

Technical specifications

Analytical quality and chain of custody

Every lot of tirzepatide is synthesized in registered facilities, with independent analytical verification by third-party laboratories and full chain-of-custody documentation. The certificate of analysis (COA) for each lot can be reviewed before purchase, recording HPLC purity and the other quality-control parameters used to release the material.

Reconstitution and laboratory handling

As a bench procedure, the lyophilized vial is reconstituted with a known volume of a suitable solvent, added along the inner wall of the vial, followed by gentle swirling until fully dissolved, without vigorous shaking. The reconstituted solution should be kept refrigerated and protected from light, and used in controlled assays within the stability period validated by the laboratory. Handling must be performed only by qualified personnel, in a bench environment suitable for in vitro experimentation, with lot number and storage conditions documented according to good laboratory practice.

Frequently asked questions

What is the purity of the tirzepatide supplied?

≥98% by HPLC, with the lot-specific value reported on the certificate of analysis (COA).

What are the synonyms and identifiers of tirzepatide?

Tirzepatide (also LY3298176 in the literature) is identified by PubChem CID 166567236, CAS 2023788-19-2 and molecular formula C225H348N48O68. Commercial drug names do not apply to this research reagent.

How should the compound be stored?

At -20 °C, protected from light and moisture, as a lyophilized powder until reconstitution.

Does the certificate of analysis come with the lot?

Yes, every lot has a matching COA that can be verified before purchase using the button on this page.

Who can purchase tirzepatide?

Sales are restricted to qualified researchers and institutions, for laboratory use only, as detailed in the research-use-only notice on this page.

See the peptide reference guide, the page on how every lot is tested by HPLC and COA and the molecular structure in the PubChem database.

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition. Sales are restricted to researchers and institutions.